Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. [1] First described in 1848, MM is part of...
multiple myelomaNorwaysupportive caretreatment regimensTo evaluate changes in diagnostic and therapeutic approach in multiple myeloma among Norwegian hematologists in the current decade.#This nationwide study in Norway is based on results of surveys conducted among professionally active hematologists from 2013...
© 2013 Springer Science+Business Media New York About this chapter Cite this chapter Cormack, F.C., Richard, R.E. (2013). Multiple Myeloma and the Kidney. In: Lerma, E., Rosner, M. (eds) Clinical Decisions in Nephrology, Hypertension and Kidney Transplantation. Springer, New York, NY...
Updates in Version 1.2023 of the NCCN Guidelines for Multiple Myeloma from Version 5.2022 include: MYEL-1 • Initial Diagnostic Workup: 11th bullet modiied: Plasma cell luorescence in situ hybridization (FISH) panel on bone marrow [del(13), del(17p13), t(4;14), t(11;14), t(14...
Presenting signs and symptoms of multiple myeloma (MM) include bone pain, pathologic fractures, weakness, anemia, infection (often pneumococcal), hypercalcemia, spinal cord compression, and renal failure. In approximately 30% of cases, MM is discovered through routine blood screening when patients are...
Gut microbiome alterations are closely related to human health and linked to a variety of diseases. Although great efforts have been made to understand the risk factors for multiple myeloma (MM), little is known about the role of the gut microbiome and a
Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When Using Optimized IV Fluid Management Coupled with Baseline Cardiac Workup ...
I taught university level courses in sociology and criminal justice for over 30 years but now I'm retired and at 72 was diagnosed with multiple myeloma, bone marrow cancer. This site is now a chronicle of my journey with myeloma.
Clin. Lymphoma Myeloma Leuk., 13 (2013), pp. 106-111, 10.1016/j.clml.2012.11.011 View PDFView articleView in ScopusGoogle Scholar Cataldi et al., 2017 M. Cataldi, C. Vigliotti, T. Mosca, M. Cammarota, D. Capone Emerging role of the spleen in the pharmacokinetics of monoclonal ant...
multiple myelomaNorwaysupportive caretreatment regimensObjective Evaluate changes in diagnostic and therapeutic approach in multiple myeloma among Norwegian hematologists in the current decade. Methods This nationwide study in Norway is based on results of surveys conducted among professionally active ...